← Map/THREAD · OUTCOMES
Treatment Response & Outcomes
What actually happens to people on treatment: remission, tapering, switching, long-term damage, and the questions patients ask.
Why this is a thread
The other eight threads are about mechanisms, the why of AS. This one is about the what: what happens to real people over years of treatment. Does diagnosing early change how much the spine fuses later? Can a dose be tapered once things are quiet? If one biologic fails, which one next? Do these drugs raise cancer risk over a decade? These questions are answered by registries, long-term trial extensions and patient-reported outcomes rather than lab work, and they are the papers that connect the research map to the patient registry on this site. Added October 2026 because a growing share of the strongest new papers had no mechanism thread to sit under.
36 papers on the board
Long-term functional and radiological outcomes among survivors of ankylosing spondylitis-associated cervical spine fractures: a cross-sectional follow-up study.
North American Spine Society journal
Among 97 survivors of neck fractures linked to ankylosing spondylitis, followed for a median of four years, most lived independently with mild neck pain and low disability, 96 percent of fractures had healed solidly, and half of those with spinal cord injury recovered fully. These fractures are dangerous at the time, but for those who come through them the long-term picture is better than most people would expect.
Plasma Proteomics Identifies Molecular Signatures and Biomarkers Associated with High Structural Damage in Ankylosing Spondylitis
Arthritis & Rheumatology
Measuring hundreds of blood proteins in people with ankylosing spondylitis, researchers found a five-protein signature, driven by platelet and tissue-remodelling proteins rather than classic inflammation markers, that identified those with heavy structural damage with high accuracy in a separate validation group. Bone damage in AS seems to run partly on a different track from inflammation, and a blood test for it looks feasible.
Preconception, pregnancy and postpartum periods in spondyloarthritis: Unmet needs and challenges from a patients and rheumatologists surveys
Joint Bone Spine
Surveys of French women with spondyloarthritis and their rheumatologists found that pregnancy is not discouraged and usually goes well, but women rated their worry about flares highly, had gaps in knowledge about biologics in pregnancy and delivery, and only a quarter of rheumatologists knew the pregnancy guidelines. The information gap is on both sides of the consultation.
Risk of peripheral artery disease following ankylosing spondylitis, 2012–2023: a nationwide cohort study in South Korea
Scandinavian Journal of Rheumatology
Following 2,846 people with ankylosing spondylitis and ten times as many matched controls in South Korea for four years, AS was linked to a 40 percent higher rate of peripheral artery disease, with the largest excess in women under 60. Circulation in the legs is another thing to keep an eye on, especially for younger women with AS.
What makes axial spondyloarthritis difficult to manage? A qualitative study of patient and rheumatologist perspectives
The Journal of Rheumatology
Interviews with French patients who had been through three or more biologics, and their rheumatologists, found they describe difficult-to-manage disease differently: patients talk about pain, fatigue and what they can no longer do, while doctors talk about not being able to tell inflammation from other causes. Much of what makes AS hard to manage is the conversation itself, not only the biology.
Difficult-to- manage and treatment refractory axial Spondyloarthritis: Systematic review and meta-analysis of prevalence and determinants.
Autoimmunity reviews
Pooling 11 studies of 5,648 patients, about one in ten people with axial spondyloarthritis have difficult-to-manage disease despite two or more biologics, and the strongest links were fibromyalgia, smoking and carrying HLA-B27. Persistent symptoms often reflect something other than ongoing inflammation, which changes what the next step should be.
Disease-modifying anti-rheumatic drugs and systemic glucocorticoid use and risk of vertebral fractures in axial spondyloarthropathies: a systematic review and meta-analysis.
Clinical rheumatology
Across ten studies, biologic and conventional disease-modifying drugs neither raised nor lowered the risk of spinal fractures in axial spondyloarthritis, and TNF and IL-17 drugs were no different from each other, but steroid tablets raised fracture risk by about 38 percent. Controlling inflammation does not by itself protect the spine from breaking, so bone health needs its own attention, and steroids are best kept to a minimum.
Early diagnosis of axial spondyloarthritis is associated with less long-term spinal structural damage: a longitudinal analysis of the Swiss Clinical Quality Management in rheumatic diseases registry.
Arthritis & rheumatology (Hoboken, N.J.)
In a Swiss registry of 376 people followed for an average of 11 years, those diagnosed within two years of their first back symptoms developed less spinal fusion on X-ray than those diagnosed later, even though short-term treatment responses were the same. Getting a diagnosis early appears to protect the spine over decades, which is the strongest argument yet against the long diagnostic delays most people with AS experience.
Impact of bimekizumab on CANDEN spinal MRI inflammation & structural lesions in radiographic axial spondyloarthritis: 2-year phase 3 results.
Rheumatology (Oxford, England)
In 102 people with radiographic axial spondyloarthritis scanned repeatedly over two years on bimekizumab (Bimzelx), spinal inflammation on MRI fell sharply by 16 weeks and stayed down, fat lesions rose a little early then stopped changing, and erosion and new bone barely moved. The inflammation the drug is aimed at clears quickly and the structural damage that worries people most showed minimal change over two years.
Impact of Dual Interleukin-17A and Interleukin-17F Inhibition with Bimekizumab on Inflammatory and Structural Lesions in Axial Spondyloarthritis: MRI and Radiographic Outcomes from the Phase 3 BE MOBILE 1 and 2 Studies and their Open-Label Extension.
Arthritis & rheumatology (Hoboken, N.J.)
Across both bimekizumab (Bimzelx) phase 3 trials, MRI inflammation in the sacroiliac joints and spine dropped substantially within a year, erosion scores fell gradually, and X-rays at two years showed almost no progression in either the joints or the spine. For a drug this new, that is early evidence it may slow structural damage, not just symptoms, though two years is short for a disease measured in decades.
Male sexual dysfunction associated with TNF-α inhibitors: an indication-stratified global pharmacovigilance analysis.
Frontiers in pharmacology
Searching the WHO global side-effect database, researchers found no overall link between TNF blockers and male sexual dysfunction, but among reports from people with ankylosing spondylitis there was a modest excess for adalimumab and etanercept that did not hold up at the level of specific symptoms. The authors call it hypothesis-generating, which is fair: worth knowing about, not a reason to change treatment.
Predicting disease flares in axial spondyloarthritis using different machine learning models in the METEOR-SpA registry.
RMD open
Using registry data on people with axial spondyloarthritis on biologics, a model built from eight routine measures, current and previous disease activity, sex, flare history, enthesitis, infliximab use, the doctor's global assessment and CRP, predicted flares moderately well in its own data and only modestly in an outside registry. Flare prediction is not ready to guide individual treatment changes, but the list of what predicts a flare is itself useful.
Real-world drug survival and treatment outcome of ixekizumab in patients with spondyloarthropathies.
Frontiers in immunology
In a real-world cohort on ixekizumab (Taltz), about 60 percent of people with ankylosing spondylitis were still on the drug at one year and the median time on treatment was just under two years, with lack of effect the main reason for stopping and side effects uncommon. Starting it earlier in the treatment sequence, rather than third-line or later, more than halved the chance of stopping.
Residual activated Th17 cells during low disease activity are associated with disease worsening in radiographic axial spondyloarthritis: A pilot study.
Joint bone spine
In 21 people with radiographic axial spondyloarthritis whose disease looked quiet, those with more activated Th17 cells still circulating were far more likely to lose control over the next six months; nearly half flared, versus none in the low-Th17 group. Feeling well and having a low score may not mean the inflammatory engine has switched off, and a blood test might one day tell the difference.
Spondyloarthritis Research and Treatment Network Recommendations for the Referral of Adults With Chronic Back Pain and Suspected Axial Spondyloarthritis to a Rheumatologist.
ACR open rheumatology
US experts and patients built a points-based referral rule for adults under 45 with chronic back pain: features such as uveitis, raised inflammatory markers, a family history, HLA-B27, inflammatory bowel disease, imaging signs, psoriasis and a good response to anti-inflammatories each add to a score, and three or more points means see a rheumatologist. It targets a diagnostic delay that in the US runs up to 14 years.
Two patterns of sacroiliac joint bone marrow oedema are apparent in AxSpA determined by HLA-B27 status, body mass index or psoriasis.
Joint bone spine
MRI scans of 203 people with axial spondyloarthritis showed two different patterns of inflammation in the sacroiliac joints: a lower pattern tied to HLA-B27, male sex and X-ray damage, and an upper pattern tied to higher body weight, psoriasis and older age, which responded well to biologics. The disease may follow somewhat different paths depending on genetics versus mechanical load, and the scan can show which.
Enhancing diagnostic accuracy in axial spondyloarthritis through centralised clinical and imaging evaluation: results from a prospective multicentre project.
Annals of the rheumatic diseases
When 969 suspected cases of axial spondyloarthritis were re-reviewed by a central expert panel, a third of the local diagnoses were overturned, usually because imaging had been over-read and the back pain was mechanical, while most local rulings-out were confirmed. Misdiagnosis in both directions is common enough that a second expert look at the scans is worth asking for when the diagnosis feels uncertain.
Automated detection of active and structural MRI lesions in the sacroiliac joints in axial spondyloarthritis: training and validation across 3 phase III clinical trial datasets.
Annals of the rheumatic diseases
A deep-learning system trained on one secukinumab trial and tested on two others detected fusion, erosion and fat changes in sacroiliac joint MRIs about as well as expert readers agree with each other, with active inflammation the hardest to call. Automated reading of these scans is approaching clinical quality, which could shorten the queue for a confident diagnosis.
Clinical Outcomes of Venous Thromboembolism in Patients with Ankylosing Spondylitis vs. Other Immune-mediated Inflammatory Diseases: Insights from the RIETE Registry.
Thrombosis and haemostasis
In a registry of over 112,000 people treated for blood clots, those with ankylosing spondylitis had similar death and bleeding rates to people with other inflammatory diseases, but were seven times more likely than non-inflammatory patients to have a second clot, and those who stopped blood thinners before a year did worse. If you have AS and have had a clot, longer anticoagulation may be warranted; it is worth raising with whoever manages it.
Comparative effectiveness of exercise interventions for axial spondyloarthritis: a systematic review and network meta-analysis.
Annals of physical and rehabilitation medicine
Pooling 59 randomised trials of 3,404 people, every structured exercise type beat usual care on disease activity, function and pain, with Pilates showing the largest gains on symptoms and function, yoga easing pain, and Qigong the only one that also lowered blood inflammation markers; none was clearly superior overall. The best exercise for AS is the one you will actually keep doing, and the evidence now supports several.
Effects of home-based exercise on disease activity, spinal mobility, functionality and systemic inflammatory indices in ankylosing spondylitis: A randomized controlled trial.
Journal of back and musculoskeletal rehabilitation
A six-week home exercise programme for ankylosing spondylitis improved spinal mobility within the exercise group but made no measurable difference to disease activity, function or blood inflammation compared with controls. Six weeks of unsupervised exercise is probably too little to shift the disease itself, which is a useful corrective to expecting quick results.
Fruit and vegetable intake as a mediator in the association between ultra-processed food and disease activity in ankylosing spondylitis.
Clinical rheumatology
Among 104 people with ankylosing spondylitis in Türkiye, eating more ultra-processed food went with higher disease activity, partly because it displaced fruit and vegetables, which were independently linked to lower activity. It is a snapshot rather than a trial, so it cannot prove diet changes the disease, but it points the same way as the gut-microbiome research.
Prevalence and clinical factors associated with difficult-to-manage axial spondyloarthritis: a multicentre Italian cohort study with meta-analysis.
Therapeutic advances in musculoskeletal disease
In 252 Italian patients, about 6 percent met the new definition of difficult-to-manage axial spondyloarthritis, persistent disease despite proper treatment, and 3 percent were truly treatment-refractory. Most people whose disease seems stuck are not actually resistant to drugs, which points to other factors, such as pain sensitisation or comorbidity, worth checking before another switch.
Ten-Year Public Expenditure Savings Associated with TNF Inhibitor Biosimilars under Australia's Pharmaceutical Benefits Scheme.
Clinical pharmacology and therapeutics
Biosimilar versions of TNF blockers saved Australia's Pharmaceutical Benefits Scheme about 562 million dollars over ten years, with etanercept biosimilars delivering most of it and adalimumab less because its biosimilars arrived late; ankylosing spondylitis was the second-largest source of savings after rheumatoid arthritis. For Australians on a TNF blocker, this is the system-level reason a biosimilar switch may be suggested.
Thoracolumbar Spine Trauma Outcomes: Effect of Ankylosing Spondylitis and Diffuse Idiopathic Skeletal Hyperostosis.
The Journal of the American Academy of Orthopaedic Surgeons
Among 189 people with thoracolumbar spine injuries, those with ankylosing spondylitis or DISH were older, were injured more often by simple falls, needed bigger operations with more levels fused, and were more likely to die in hospital or go to long-term care, though nerve recovery was similar. A stiff spine turns a minor fall into a major injury, which is the practical reason fall prevention matters so much in AS.
What Defines an MRI Considered Indicative of Axial Spondyloarthritis in the Sacroiliac Joints: A Systematic Literature Review.
The Journal of rheumatology
Reviewing 30 studies, the authors found the usual MRI sign of axial spondyloarthritis, bone marrow swelling in the sacroiliac joints, also shows up in healthy people and women after childbirth, while erosion and fat change next to that swelling are far more specific. MRI definitions are being tightened, which should mean fewer wrong diagnoses in both directions.
Longitudinal monitoring of adalimumab levels and anti-adalimumab antibodies in Chinese patients with ankylosing spondylitis: a prospective cohort study
Frontiers in Immunology
Tracking 140 Chinese patients on adalimumab (Humira) alone for ankylosing spondylitis, 90 percent developed antibodies against the drug within months, and those with high antibody levels had far lower drug concentrations and roughly half the response rate of those with low levels. Measuring drug and antibody levels in the blood could show early who is heading for treatment failure, and the study sets target concentrations for that.
Survival Outcomes in Older Adults with Axial Spondyloarthritis and Concomitant Cancer
Arthritis Care & Research
In US Medicare data on over 6,000 older adults with axial spondyloarthritis who developed breast, prostate, lung or bowel cancer, five-year survival was the same as for people without axSpA, and slightly better for bowel cancer. Having axSpA does not appear to worsen your chances if you get one of these common cancers later in life.
Korean College of Rheumatology treatment recommendations for patients with axial spondyloarthritis: 2026 update.
Journal of rheumatic diseases
Korea's 2026 rheumatology guideline sets out 20 recommendations for axial spondyloarthritis: treat to a target, measure disease with ASDAS, stop smoking and exercise, start with anti-inflammatories, and move to a TNF, IL-17 or JAK drug when those fail, with guidance on switching, tapering and safety checks. It is a clear, current picture of what standard care looks like in 2026.
Therapeutics in Axial Spondyloarthritis: A Review of What Works - SPARTAN 2026 Annual Meeting Proceedings.
Current rheumatology reports
A 2026 expert review concludes that TNF, IL-17 and JAK drugs all control symptoms in axial spondyloarthritis, that evidence for slowing spinal damage is strongest for TNF blockers and not yet established for JAK inhibitors, and that structured exercise, in sessions of an hour or less, measurably improves activity, function, pain and fatigue. Obesity predicts worse disease and a weaker response to TNF drugs.
Cardiovascular and Thromboembolic Risk With Upadacitinib in Spondyloarthritis and Inflammatory Bowel Disease: A Meta-Analysis of Randomized Controlled Trials.
Journal of cardiovascular pharmacology
Pooling eight randomised trials of 4,433 people with spondyloarthritis or inflammatory bowel disease, upadacitinib (Rinvoq) showed no increase in heart attacks, strokes or blood clots compared with placebo, though events were rare enough that the result cannot rule out a small risk. The signal that led to warnings on JAK drugs came from older rheumatoid arthritis patients; in this population, the trials so far are reassuring but not conclusive.
Clinical and MRI features associated with remission following biological therapy in axial spondyloarthritis.
Clinical rheumatology
In 41 people starting their first biologic for axial spondyloarthritis, those whose baseline MRI showed more erosion of the sacroiliac joints, and more active inflammation, were the most likely to reach remission by 16 weeks. The damage and inflammation a scan shows before treatment may help predict who will do best on a biologic, which is the opposite of assuming a worse-looking scan means a worse outlook.
Paradoxical psoriasis in axial spondyloarthritis and rheumatoid arthritis treated with b/tsDMARDs: a retrospective cohort study.
Clinical rheumatology
Among 1,588 people on biologics for axial spondyloarthritis or rheumatoid arthritis, about 2 percent developed a psoriasis-like rash caused by the drug, almost always a TNF blocker, with smoking the only independent risk factor; stopping the drug cleared it in most, and switching to a non-TNF drug worked. If a new rash appears on a TNF blocker, it may be the drug, and there are good alternatives.
Association between type 2 diabetes and short-term clinical response to TNF inhibitors in patients with ankylosing spondylitis: a propensity score-matched retrospective cohort study.
Clinical rheumatology
In a single-centre study of people with ankylosing spondylitis starting a TNF blocker, those with type 2 diabetes were far less likely to respond in the short term, 20 percent versus 75 percent in the matched comparison. The authors are careful to call it a signal rather than a proof, since blood sugar control and weight were not fully accounted for, but if you have both conditions it is a conversation worth having before judging a drug a failure.
Association of dietary sodium intake with IL-17-mediated diseases in the UK biobank.
Clinical nutrition ESPEN
In the UK Biobank, higher estimated salt intake went with slightly higher odds of IL-17-driven conditions such as psoriasis, psoriatic arthritis and rheumatoid arthritis, but there was no link at all with ankylosing spondylitis. Despite plausible lab reasons to expect one, this large study does not support cutting salt as a way to influence AS.
Biomarkers in axial spondyloarthritis diagnosis: from clinical signs to multi-omics integration.
Frontiers in immunology
This review maps every kind of marker used to diagnose axial spondyloarthritis, from HLA-B27 and CRP through genomics and metabolomics to MRI read by deep-learning models, and how combining them is starting to shorten the typical two-to-six-year wait for a diagnosis. For anyone who waited years, it explains why, and what is changing.